Pimozide can also overcome the resistance that Flt3 confers to AML cells to treatment with PI3K/Akt inhibitors, by attenuating STAT5 activation, which in turn prevents the activation of mTOR and decreases the expression of MCL-1 [107]. The gene discussed is STAT5B; the disease is acute myeloid leukemia.